Related Experiment Video
Updated: Nov 30, 2025

07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.4K
Summary
VS-6766, a novel dual RAF-MEK inhibitor, demonstrated safety and efficacy in early trials for solid tumors and multiple myeloma with RAS-RAF mutations.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- RAF and MEK proteins are key components of the RAS-RAF-MEK-ERK signaling pathway.
- Mutations in RAS and RAF genes are common drivers in various solid tumors and multiple myeloma.
- Targeting this pathway offers a therapeutic strategy for cancers with these mutations.

